ChemicalBook >
Produktkatalog >
Aktive pharmazeutische Wirkstoffe (APIs) >
Kreislaufsystem Drogen >
Antihypertensiva >Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthren-17,2'(5'H)-furan]-3,5'(2H)-dion, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-Hexadecahydro-10,13-dimethyl-, [6R-(6α,7α,8β,9α,10β,13β,14α,15α,16α,17β)]-
Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthren-17,2'(5'H)-furan]-3,5'(2H)-dion, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-Hexadecahydro-10,13-dimethyl-, [6R-(6α,7α,8β,9α,10β,13β,14α,15α,16α,17β)]-
|
|
- CAS-Nr.
- 67392-87-4
- Bezeichnung:
- Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthren-17,2'(5'H)-furan]-3,5'(2H)-dion, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-Hexadecahydro-10,13-dimethyl-, [6R-(6α,7α,8β,9α,10β,13β,14α,15α,16α,17β)]-
- Englisch Name:
- Drospirenone
- Synonyma:
- Drospirenon;Drospirenona;DROSPIRENONE INTERMEDIATE;17-Hydroxy-7β-(hydroxyMethyl)-15β,16β-Methylene-17α-pregn-3,5(6)-diene-21-carboxylic Acid, -Lactone;6b,7b;ZK 3059;ZK 30595;Spironone;Drospirone;arbolactone
- CBNumber:
- CB8695608
- Summenformel:
- C24H30O3
- Molgewicht:
- 366.5
- MOL-Datei:
- 67392-87-4.mol
|
Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthren-17,2'(5'H)-furan]-3,5'(2H)-dion, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-Hexadecahydro-10,13-dimethyl-, [6R-(6α,7α,8β,9α,10β,13β,14α,15α,16α,17β)]- Eigenschaften
- Schmelzpunkt:
- 196-200°C
- alpha
- -180 º (c=0.5, chloroform)
- Siedepunkt:
- 552.2±50.0 °C(Predicted)
- Dichte
- 1.26±0.1 g/cm3(Predicted)
- storage temp.
- 2-8°C
- L?slichkeit
- DMSO: ≥15
- Aggregatzustand
- powder
- Farbe
- white to tan
- Optische Aktivit?t
- [α]/D -180 to -195°, c = 1 in methanol
- InChIKey
- METQSPRSQINEEU-URUUTGNFNA-N
- SMILES
- C[C@]12CC[C@]3([H])[C@]4(CCC(=O)C=C4[C@@H]4C[C@@H]4[C@@]3([H])[C@]1([H])[C@@H]1C[C@@H]1[C@]12CCC(=O)O1)C |&1:1,4,6,13,15,16,18,20,22,23,r|
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
Bildanzeige (GHS) |
|
Alarmwort |
Achtung |
Gefahrenhinweise |
Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
H360 |
Kann die Fruchtbarkeit beeintr?chtigen oder das Kind im Mutterleib sch?digen. |
Fertility (Fruchtbarkeit) |
Kategorie 1 |
Achtung |
src="/GHS08.jpg" width="20" height="20" /> |
|
|
Sicherheit |
P201 |
Vor Gebrauch besondere Anweisungen einholen. |
P202 |
Vor Gebrauch alle Sicherheitshinweise lesen und verstehen. |
P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
P308+P313 |
BEI Exposition oder falls betroffen: ?rztlichen Rat einholen/?rztliche Hilfe hinzuziehen. |
P405 |
Unter Verschluss aufbewahren. |
P501 |
Inhalt/Beh?lter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen. |
|
Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthren-17,2'(5'H)-furan]-3,5'(2H)-dion, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-Hexadecahydro-10,13-dimethyl-, [6R-(6α,7α,8β,9α,10β,13β,14α,15α,16α,17β)]- Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
The steroid drospirenone in combination with the estrogen agonist ethinylestradiol was
introduced in Germany as a new oral contraceptive for women. This analog of the
aldosterone antagonist spironoiactone can be synthesized in five steps from 3β-hydroxy-
15β,16β-methylene-5-androsten-l7-one. Since its binding profile for steroid receptors is
very similar to progesterone, drospirenone mimics the progestogen agonistic activity as
well as the anti-androgenic and anti-mineralocorticoid properties of the endogenous
hormone. In rats, drospirenone inhibited ovulation at 6.3 mglkglday p.o. Compared with
currently available progestins which lack anti-mineralocorticoid activity, drospirenone did
not cause weight gain that could result from fluid retention in clinical studies. Its
combination with ethinylestradiol was well tolerated and did not engender adverse effects
on blood pressure or plasma lipid levels. Drospirenone is rapidly absorbed in man with an
oral bioavailability of 76%. It is extensively metabolized since over 20 different metabolites
were observed in the urine and in the feces, resulting for instance from hydrolysis of the
lactone in the plasma or reductive conjugation of the enone to the 3-sulfate ester of 45
dihydrodrospirenone. Its elimination is bi-exponential with an initial and a terminal half-life
of 2 and 25-33h respectively.
Chemische Eigenschaften
Off-White Crystalline Powder
Verwenden
Drospirenone has been used as a progestogen agent in pond snail and fish.
Allgemeine Beschreibung
Drospirenone, 3-oxo-6β,7β:15β,16β-dimethylene-17α-pregn-4-en-21,17-carbolactone,differs structurally from all the other commercially availableprogestins. Its structure is similar to that of spironolactone,an MR antagonist, and it does have antimineralocorticoidactivity as well as progestational activity. It isalso reported to have some antiandrogenic effects. Thespirolactone at C17 and the two cyclopropyl groups at C6-C7 and C15-C16 contribute to these unique actions.Drospirenone is the progestin component in the newer oralcontraceptives, Yasmin and Yaz, and in the HRT product,Angeliq.
Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthren-17,2'(5'H)-furan]-3,5'(2H)-dion, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-Hexadecahydro-10,13-dimethyl-, [6R-(6α,7α,8β,9α,10β,13β,14α,15α,16α,17β)]- Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthren-17,2'(5'H)-furan]-3,5'(2H)-dion, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-Hexadecahydro-10,13-dimethyl-, [6R-(6α,7α,8β,9α,10β,13β,14α,15α,16α,17β)]- Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 434)Lieferanten
67392-87-4(Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthren-17,2'(5'H)-furan]-3,5'(2H)-dion, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-Hexadecahydro-10,13-dimethyl-, [6R-(6α,7α,8β,9α,10β,13β,14α,15α,16α,17β)]-)Verwandte Suche:
8-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decan-7,9-dionmonohydrochlorid
TANDOSPIRONE
Buspiron
Chrysen
Testosteronpropionat
5-Hexyldihydro-5-methylfuran-2(3H)-on
Methyltestosteron
(E)-Docos-13-ensure
Topteron
Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthren-17,2'(5'H)-furan]-3,5'(2H)-dion, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-Hexadecahydro-10,13-dimethyl-, [6R-(6α,7α,8β,9α,10β,13β,14α,15α,16α,17β)]-
- 7β-(HydroxyMethyl)-15β,16β-Methylene-17α-pregn-3,5(6)-diene-21,17-carbolactone
- Drospirenone(Dihydrospirorenone)
- Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione
- Drospirenone (USP32)
- Drospirenone, >=98%
- Drosporenone
- 6b,7b:15b,16b-Dimethylen-3-oxo-17a-pregn-4-ene-21
- 6β,7β:15β,16β -Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone
- Drospirenone for peak identification
- 17-beta))-16-alpha
- 6-beta,7-beta
- arbolactone
- ,5’(2h)-dione,1,3’,4’,6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-
- 1,2-dihydrospirorenone
- 15-beta,16-beta-dimethylene-3-oxo-17-alpha-pregn-4-ene-21,17-c
- ZK 3059
- DEHYDROSPIRORENONE
- 6b,7b:15b,16b-Dimethylen-3-oxo-17a-pregn-4-ene-21,17-carbolactone
- 6,7,15,16-Dimethylene-3-oxo-4-androstene-[17(-1’)-spiro-5’]perhydrofuran-2’-one
- ZK 30595
- dimethyl-,(6r-(6-alpha,7-alpha,8-beta,9-alpha,10-beta,13-beta,14-alpha,15-alph
- spiro(17h-dicyclopropa(6,7:15,16)cyclopenta(a)phenanthrene-17,2’(5’h)-furan)-3
- Drospirenone, USP
- 3-Oxo-6β,7β:15β,16β-diMethylene-17α-pregn-4-en-21,17-carbolactone
- 6b,7b
- 6b,7b,15b,16b-Dimethylene-3-oxo-4-androstene-[17(b-1-spiro-5perhydrofuran-2one
- (6R,17S)-1,3',4',6α,7α,8β,9α,10,11,12,13,14α,15α,16α,20,21-Hexadecahydro-10β,13β-dimethylspiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione
- Dorospirenone
- Drospirenone (200 mg)
- dihydrospirorenone
- DROSPIRENONE
- Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, [6R-(6alpha,7alpha,8beta,9alpha,10beta,13beta,14alpha,15alpha,16alpha,17b
- 15b,16b-dimethylen-3-oxo-17a-pregn-4-ene-21,17-carbolactone
- Drospirenone-20,20,21,21-d4
- Drospirenone CRS
- Drospirenone>
- Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-
- (2'S,4aR,4bS,6aS,7aS,8aS,8bS,8cR,8dR,9aR)-4a,6a-dimethyl-4,4a,4b,5,6,6a,7a,8,8a,8b,8c,8d,9,9a-tetradecahydro-3'H-spiro[cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthrene-7,2'-furan]-2,5'(3H,4'H)-dione
- Drospirenone USP/EP/BP
- (4aR,4bS,6aS,7S,7aS,8aS,8bS,8cR,8dR,9aR)-4a,6a-dimethyl-3',4,4a,4b,4',5,6,6a,7a,8,8a,8b,8c,8d,9,9a-hexadecahydro-5'H-spiro[cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthrene-7,2'-furan]-2,5'(3H)-dione
- Drospirenone D4Q: What is
Drospirenone D4 Q: What is the CAS Number of
Drospirenone D4 Q: What is the storage condition of
Drospirenone D4 Q: What are the applications of
Drospirenone D4
- DrospirenoneQ: What is
Drospirenone Q: What is the CAS Number of
Drospirenone Q: What is the storage condition of
Drospirenone Q: What are the applications of
Drospirenone
- Drospirenone (1229409)
- 17-Hydroxy-7β-(hydroxyMethyl)-15β,16β-Methylene-17α-pregn-3,5(6)-diene-21-carboxylic Acid, -Lactone
- DROSPIRENONE INTERMEDIATE
- Drospirenon
- Drospirenona
- Flexor screw ketone
- Drospirenone Estrogen Hormone Raw Powder
- rospirenone
- Spironone
- 1-[1-[4-[4-[4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-3,6-dihydropyridin-1(2H)-yl]-1-oxobutyl]phenyl]-1,2,3,6-tetrahydropyridin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one.
- Drospirone
- Drospirenone-d4 (3',3',4',4'-d4)
- 5a,7a-dimethyl-1,1a,5,5a,5b,6,7,7a,8a,9,9a,9b,9c,9d-tetradecahydro-3'H-spiro[cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthrene-8,2'-furan]-3,5'(4H,4'H)-dione
- 67392-87-4
- 7392-87-4
- 266-679-2